Outcome and safety of rechallenge [177Lu]Lu-PSMA-617 in patients with metastatic prostate cancer.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Data are sparse regarding the feasibility of radioligand therapy (RLT) with [177Lu]Lu-PSMA-617 as a retreatment. We aimed to assess the outcome and safety of rechallenge PSMA-RLT in patients with progressive prostatic cancer who previously benefited from this therapy.

Related collections

Author and article information

Journal

PubMed ID:: 30474706

DOI:: 10.1007/s00259-018-4222-x

Keywords: Lutetium-177,Radioligand therapy,Prostate cancer,CRPC,Recurrence,PSMA

Data availability:

Keywords: Lutetium-177, Radioligand therapy, Prostate cancer, CRPC, Recurrence, PSMA

Comments

Comment on this article

scite_

Smart Citations

Citing PublicationsSupportingMentioningContrasting

View Citations

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

Cited by 27

See all cited by